Delivery Order SPE2DB22D2214-SPE2DB25FS5DU

Award Date 5/29/25
Potential Completion Date 6/20/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $10,336.32 firm fixed-price delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of 4,568,621,605 BOTOX 100 unit vials, with a completion date of July 15, 2025. The contract is not set aside and is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
This is a $10,336.32 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,568,568,836 units of BOTOX 100 UNIT VIALS. The contract has an ultimate completion date of July 8, 2025 and was awarded on June 13, 2025. The contract is not set-aside and allows for the delivery of both brand-name and generic medications. Amerisourcebergen Drug Corp holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $58,213.00 firm fixed-price contract is for the delivery of BOTOX 200 unit vials. This delivery order falls under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support...
This is a firm-fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $85,479.00, is for the delivery of 4,568,523,812 BOTOX 200 UNIT VIALS. The contract has an ultimate completion date of July 3, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,767.00 firm fixed-price contract is for the delivery of 4,568,530,658 units of BOTOX 100 unit vials, with a completion date of July 3, 2025. The contract is not set aside for any specific socioeconomic category. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 100-unit vials of BOTOX. The $4,306.80 firm fixed-price contract has a completion date of July 15, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 200-unit vials of Botox. The contract is a firm-fixed-price delivery order with a ceiling value of $13,971.12 and an ultimate completion date of October 17, 2024. The contract does not have a set-aside designation. Amerisourcebergen has been awarded numerous federal contracts and indefinite delivery contracts (IDCs) by various defense and...
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) to provide 100-unit vials of BOTOX. The $5,168.16 firm fixed price contract has a performance period ending on July 7, 2025 and does not utilize any set-aside designations. Amerisourcebergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical...
This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of 100-unit vials of BOTOX, a specialty medication, at a firm fixed price of $8,613.60. The delivery order has an ultimate completion date of February 19, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BOTOX 100 UNIT VIALS, with a ceiling value of $2,584.08 and a completion date of June 20, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor, and there...
  • SPE2DB22D2214
    Indefinite Delivery Contract
  • SPE2DB22D2214-SPE2DB25FS5DU
    Delivery Order

This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $10,257.48 firm-fixed-price contract is for the delivery of 4,568,424,818 BOTOX 200 UNIT VIALS. The contract has an ultimate completion date of June 20, 2025 and was awarded on May 29, 2025. This delivery order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated as SPE2DX, which provides comprehensive global pharmaceutical support to military healthcare programs through December 2026. The contract is not set-aside and is open to full and open competition.

Generated 8/28/25, 10:08 AM